Addressing the Global Disparities in Access to Treatment in Spinal Muscular Atrophy

Area of Science:

• Neurology
• Genetics
• Public Health

Background:

• Novel disease-modifying therapeutics have significantly improved life expectancy and motor function in spinal muscular atrophy (SMA).
• Current therapeutic benefits are well-established, but clinical trials lack global representation, primarily focusing on high- and middle-income countries.
• Despite approvals in over 50 countries, access to these life-changing SMA medications remains limited for many, potentially exacerbating healthcare disparities.

Purpose of the Study:

• To identify sources of health inequalities in spinal muscular atrophy (SMA) care.
• To propose strategies for improving equitable access to SMA screening and treatments.
• To address the evolving SMA phenotype and increasing adult patient population.

Main Methods:

• Review of current therapeutic approaches and access barriers for spinal muscular atrophy (SMA).
• Identification of clinical opportunities including expanded screening, patient registries, and telehealth.
• Exploration of technological advancements like artificial intelligence for screening and monitoring.
• Analysis of regulatory and policy changes needed to reduce medication costs.

Main Results:

• The standard SMA phenotype is changing, with a growing adult patient cohort necessitating adapted therapeutic strategies.
• Novel technologies like AI and telehealth offer potential for expanded screening and monitoring.
• Equitable access requires addressing disparities in screening availability, care continuity, and medication cost.

Conclusions:

• Ensuring equitable healthcare access for spinal muscular atrophy (SMA) necessitates expanding screening, improving care continuity, and implementing supportive regulatory and drug policies.
• Addressing global disparities in access to SMA therapeutics is crucial for promoting health equity.
• Further research into SMA population disparities and globally diverse clinical trials is essential to bridge the care gap.